Please try another search
NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.
Name | Age | Since | Title |
---|---|---|---|
Bruno Lafont | - | 2006 | Co-Founder, COO & Director |
Carole Clair | - | - | Scientific Advisor |
Stuart Ferguson | - | - | Scientific Advisor |
Scott Leischow | - | - | Scientific Advisor |
Paul Aveyard | - | - | Scientific Advisor |
Francois Brackman | - | - | Scientific Advisor |
Ignacio Faus | - | 2023 | CEO & Chairman |
Yannick Pletan | 70 | - | Director |
Francis Ahner | - | - | Director |
Mitch Nides | - | - | Scientific Advisor |
Michel Huc | - | - | Director |
Dominique Cote | - | 2023 | Independent Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review